An observational study in Gastric Cancer, Preneoplastic Condition and Early Gastric Cancer, sponsored by Instituto Portugues de Oncologia, Francisco Gentil, Porto. Completed at 1 site in Portugal. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-29.
Sponsored by Instituto Portugues de Oncologia, Francisco Gentil, Porto · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Stomach Neoplasms with a site in Portugal — 6 open to participants now, 11 under way, 4 of them phase 3. Stomach Neoplasms · Portugal.
Among the 41 studies in Stomach Neoplasms with a site in Portugal, this one is the 9th largest by enrollment of the 10 observational ones that give a count, is one of 6 that started in 2021, is one of 10 observational ones, and was the 27th registered.
3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.
Browse Stomach Neoplasms studies →6 of the 41 studies in Stomach Neoplasms with a site in Portugal are open now. Recruiting first, the newest first:
Unidade Local de Saúde do Alto Ave, EPE · Sites in Portugal
Ages 18+
Daiichi Sankyo · Sites in Portugal, United States, Argentina and 23 more countries
Ages 18+
University of Maia · Sites in Portugal
Ages 18+
Hospital Beatriz Ângelo · Sites in Portugal
Ages 40–80
Instituto Portugues de Oncologia, Francisco Gentil, Porto · Sites in Portugal
Ages 45+
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 16
First in 1999; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is below the median of 278 across 792 observational studies indexed under Stomach Neoplasms.
Median enrollment 296 across the 31 interventional studies, 325 across the 10 observational. Of the 26 that completed or were terminated, 12 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 41 have an industry lead sponsor. The 10 most frequent:
Instituto Portugues de Oncologia, Francisco Gentil, Porto is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Instituto Portugues de Oncologia, Francisco Gentil, Porto has 2 studies filed under Stomach Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Stomach Neoplasms with a site in Portugal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04613570Instituto Portugues de Oncologia, Francisco Gentil, PortoSUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up | 2026-12-31 |
| NCT07920068Unidade Local de Saúde do Alto Ave, EPEEpinephrine 1:100,000 Versus 1:500,000 During Gastric Endoscopic Submucosal Dissection | 2027-02-27 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies in Stomach Neoplasms with a site in Portugal, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Introduction: Traditionally, White Light Endoscopy (WLE), enhanced by biopsies following the updated Sydney system guidelines, has been the benchmark for diagnosing and classifying gastric preneoplastic conditions. Nevertheless, the pronounced interobserver variability and the often weak correlation between endoscopic observations and histopathological results have driven the increasing adoption of virtual chromoendoscopy (VCE). VCE technologies have demonstrated greater effectiveness in identifying these conditions compared to WLE, with Narrow Band Imaging (NBI) being particularly notable. Significantly, NBI has played a key role in validating the Endoscopic Grading of Gastric Intestinal Metaplasia (EGGIM) system. However, data on the effectiveness of other VCE technologies in this domain is relatively sparse in Europe, specifically with Blue Light Imaging (BLI), despite the promising diagnostic performance demonstrated with this technology.
Primary aim: to assess the diagnostic accuracy of BLI and to externally validate the applicability of EGGIM classification for staging GIM.
Material and methods: a multicentric cohort study will be performed involving centres from two European countries (Portugal, Italy). Consecutive patients performing upper gastrointestinal endoscopy will be evaluated by WLE and BLI. Random biopsies or targeted plus random biopsies will be performed in order to determine de accuracy of BLI system to detect and stage GIM.
Expected results: We anticipate that BLI would enable us to assess the extension of GIM without the need for biopsies. If observed, this would overall improve the upper GI endoscopy accuracy.
Patients referred to the endoscopy department of a tertiary care center for screening or surveillance upper gastrointestinal endoscopy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To determine the inter-observer agreement and accuracy of BLI system for the diagnosis and endoscopic staging of GIM
For accuracy: A per-biopsy analysis will be performed comparing diagnostic perception per site biopsied (ie, accuracy of WLE or BLI for each site observed vs that result). For inter-observer agreement: after following educational set, inter-observer agreement for WLE and BLI will be assessed (see phase 2).
Time frame: During the 3 months after finishing histopathological analysis of biopsies (an average of 17 months)
To externally validate the EGGIM score classification using BLI
For accuracy: A per-patient analysis will be performed comparing WLE and BLI accuracy for Operative Link on Gastritis Assessment for Intestinal Metaplasia (OLGIM) III/IV (ie, accuracy of EGGIM estimated by each endoscopist using WLE or BLI towards OLGIM III/IV). For inter-observer agreement: after completion phase 3, video records will be assessed by 1 endoscopist and inter-observer agreement for EGGIM classification, using BLI system, will be evaluated
Time frame: During the 12 months after finishing histopathological analysis of biopsies (an average of 17 months)
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2021 to primary completion in Dec 2023, 33 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Portugues de Oncologia, Francisco Gentil, Porto